Forum > Topic Details

Dapoxetine, the active ingredient in Duratia 90 mg, is primarily metabolized in the liver by multiple enzymes, including cytochrome P450 (CYP) enzymes. The primary metabolic pathway for dapoxetine involves sequential N-demethylation and N-oxidation, primarily mediated by the CYP2D6 and CYP3A4 enzymes. CYP2D6 is the main enzyme responsible for the initial metabolism of Duratia 90 mg, while CYP3A4 contributes to its subsequent metabolism. These enzymes convert dapoxetine into its major metabolites, including desmethyldapoxetine and desmethyldapoxetine-N-oxide, which are then further metabolized and eliminated from the body. Individuals with genetic variations in CYP2D6 activity may experience differences in the metabolism of dapoxetine, potentially leading to variations in drug efficacy and tolerability. Additionally, certain medications that inhibit or induce CYP2D6 or CYP3A4 activity may affect the metabolism of dapoxetine, altering its pharmacokinetics and potentially increasing the risk of adverse effects. Overall, understanding the metabolic pathways of dapoxetine is important for optimizing its use and minimizing the risk of drug interactions and adverse reactions. It's recommended to consult with a healthcare professional or pharmacist for personalized guidance regarding the metabolism and use of Duratia 90 mg.